OGI earnings

Organigram Global Inc. (NASDAQ:OGI) (TSX:OGI), (the "Company" or "Organigram"), Canada's #1 cannabis company by market share1, is pleased to announce its results for the second quarter ended March 31, 2026 ("Q2 Fiscal 2026" or "Q2"). Q2 FISCAL 2026 HIGHLIGHTS Gross Revenue: $93.3 million (-9% year-over-year). Net Revenue: $59.8 million (-9% year-over-year). International Revenue: $6.1 million (0% year-over-year). Adjusted EBITDA2: $0.9 million (-82% year-over-year). #1 Market Share in Canada: #1 in vapes, #1 in milled flower, #1 in concentrates, #2 in flower, #2 in pre-rolls, #3 in edibles, and #5 in beverages1. Sanity Group GmbH ("Sanity Group") Acquisition: Subsequent

Organigram Global Inc. (NASDAQ:OGI) (TSX:OGI), (the "Company" or "Organigram"), Canada's #1 cannabis company by market share, announced today it will report earnings results for its second quarter fiscal 2026 ended March 31, 2026, on Tuesday, May 12, 2026, prior to market open. The Company will host a conference call to discuss its results with details as follows: Date: Tuesday, May 12, 2026 Time: 8:00 am Eastern Time To register for the conference call, please use this link: https://events.q4inc.com/analyst/574618022?pwd=FVnom6fM To ensure you are connected for the full call, we suggest registering a day in advance or at minimum 10 minutes before the start of the call. After regist

Strong year-over-year growth supported by Canadian leadership and growing international sales, improving gross margin. Organigram Global Inc. (NASDAQ:OGI) (TSX:OGI), (the "Company" or "Organigram"), Canada's #1 cannabis company by market share1, is pleased to announce its results for the first quarter ended December 31, 2025 ("Q1 Fiscal 2026" or "Q1"). Q1 FISCAL 2026 HIGHLIGHTS Gross Revenue: $97.3 million (+46% year-over-year). Net Revenue: $63.5 million (+49% year-over-year). International Revenue: $5.0 million (+51% year-over-year). Adjusted EBITDA2: $5.3 million (+273% year-over-year). #1 Market Share in Canada: #1 in vapes, #1 in milled flower, #1 in concentrates, #2

Organigram Global Inc. (NASDAQ:OGI) (TSX:OGI), (the "Company" or "Organigram"), Canada's #1 cannabis company by market share, announced today it will report earnings results for its first quarter fiscal 2026 ended December 31, 2025, on Tuesday, February 10, 2026, prior to market open. The Company will host a conference call to discuss its results with details as follows: Date: Tuesday, February 10, 2026 Time: 8:00 am Eastern Time To register for the conference call, please use this link: https://events.q4inc.com/analyst/430252525?pwd=WEt2KbHS To ensure you are connected for the full call, we suggest registering a day in advance or at minimum 10 minutes before the start of the call.

Record annual revenue, adjusted EBITDA1, and international sales. Organigram Global Inc (NASDAQ:OGI) (TSX:OGI), (the "Company" or "Organigram"), Canada's #1 recreational cannabis company by market share2, is pleased to announce record results for the fourth quarter and twelve months ended September 30, 2025 ("Q4 Fiscal 2025" or "Fiscal 2025"). All financial information in this press release is expressed in Canadian dollars ("$"). FOURTH QUARTER 2025 FINANCIAL HIGHLIGHTS Gross Revenue: $123.3 million (+76% year-over-year). Net Revenue: $80.1 million (+79% year-over-year). Adjusted Gross Margin1: $30.6 million or 38%. Adjusted EBITDA1: $9.8 million (+69% year-over-year). FISCAL 20

Organigram Global Inc. (NASDAQ:OGI) (TSX:OGI), (the "Company" or "Organigram"), Canada's #1 cannabis company by market share1, announced today it will report earnings results for its fourth quarter fiscal 2025 ended September 30, 2025, on Tuesday, December 16, 2025, prior to market open. The Company will host a conference call to discuss its results with details as follows: Date: Tuesday, December 16, 2025 Time: 8:00 am Eastern Time To register for the conference call, please use this link: https://registrations.events/direct/Q4I9676638 To ensure you are connected for the full call, we suggest registering a day in advance or at minimum 10 minutes before the start of the call. After regi

Second consecutive quarter of record revenue, strong adjusted EBITDA growth, Free Cash Flow, and continued international expansion Organigram Global Inc. (NASDAQ:OGI) (TSX:OGI), (the "Company" or "Organigram"), Canada's #1 cannabis company by market share1, is pleased to announce its record results for the third quarter ended June 30, 2025 ("Q3 Fiscal 2025" or "Q3"). Q3 FISCAL 2025 HIGHLIGHTS Record Gross Revenue: $110.2 million (+73% year-over-year, +7.2% sequential). Record Net Revenue: $70.8 million (+72% year-over-year, +7.9% sequential). International Revenue: $7.4 million (+208% year-over-year, +21% sequential). Adjusted EBITDA2: $5.7 million (+64% year-over-year, +16%

Organigram Global Inc. (NASDAQ:OGI) (TSX:OGI), (the "Company" or "Organigram"), Canada's #1 cannabis company by market share, announced today it will report earnings results for its third quarter fiscal 2025 ended June 30, 2025, on Wednesday, August 13, 2025, prior to market open. The Company will host a conference call to discuss its results with details as follows: Date: Wednesday, August 13, 2025 Time: 8:00 am Eastern Time To register for the conference call, please use this link: https://registrations.events/direct/Q4I9676685 To ensure you are connected for the full call, we suggest registering a day in advance or at minimum 10 minutes before the start of the call. After registe

Record gross revenue of $102.8 million and record net revenue of $65.6 million Adjusted EBITDA1 of $4.9 million Net income of $42.5 million Increase in anticipated Motif cost synergies to $15 million from $10 million Total cash position of $83.4 million2 and negligible debt Organigram Global Inc. (NASDAQ:OGI) (TSX:OGI), (the "Company" or "Organigram"), Canada's #1 cannabis company by market share, announced its record results for the second quarter ended March 31, 2025 ("Q2 Fiscal 2025"). The Q2 Fiscal 2025 results include a full quarter of consolidated financials from the Company's acquisition of Motif Labs Ltd. ("Motif") on December 6, 2024. Q2 FISCAL 2025 HIGHLIGHTS Gross r

  Organigram Global Inc. (NASDAQ:OGI) (TSX:OGI), (the "Company" or "Organigram"), Canada's #1 cannabis company by market share, announced today it will report earnings results for its second quarter fiscal 2025 ended March 31, 2025, on Monday, May 12, 2025, prior to market open. The Company will host a conference call to discuss its results with details as follows: Date: Monday, May 12, 2025 Time: 8:00 am Eastern Time To register for the conference call, please use this link: https://registrations.events/direct/Q4I96766371 To ensure you are connected for the full call, we suggest registering a day in advance or at minimum 10 minutes before the start of the call. After registering, a co

17% growth in net revenue to $42.7 million year-over-year $2.3 million growth in international sales year-over-year Adjusted EBITDA1 of $1.4 million versus $0.1 million in the prior year period Completed acquisition of Motif to become recreational cannabis market leader in Canada Launched Edison Sonics with proprietary FAST™ nanoemulsion technology, clinically validated to have up to 50% faster onset and nearly 2x impact of cannabinoids at peak Strong balance sheet with negligible debt, and a pro-forma cash position of $113 million2 Organigram Holdings Inc. (NASDAQ:OGI) (TSX:OGI), (the "Company" or "Organigram"), a leading licensed producer of cannabis, announced its resu

Organigram Holdings Inc. (NASDAQ:OGI) (TSX:OGI), the parent company of Organigram Inc. (together, the "Company" or "Organigram"), a leading licensed producer of cannabis, announced today it will report earnings results for its first quarter fiscal 2025 ended December 31, 2024, on Tuesday, February 11, 2025, prior to market open. The Company will host a conference call to discuss its results with details as follows: Date: Tuesday, February 11, 2025 Time: 8:00 am Eastern Time To register for the conference call, please use this link: https://registrations.events/direct/Q4I967665 To ensure you are connected for the full call, we suggest registering a day in advance or at minimum 10 min

Fiscal 2024 net revenue of $159.8 million 17.6% year-over-year growth in Organigram's recreational shipped sales in Fiscal 2024 Q4 Fiscal 2024 adjusted gross margin1 of 37% Q4 Fiscal 2024 adjusted EBITDA2 of $5.9 million or 13% of net revenue Q4 Fiscal 2024 cash flow from operations of $8.9 million Became Canada's largest cannabis company by market share following the acquisition of Motif Labs subsequent to year end Organigram Holdings Inc. (NASDAQ:OGI) (TSX:OGI), (the "Company" or "Organigram"), a leading licensed producer ("LP") of cannabis, announced its results for the fourth quarter and twelve months ended September 30, 2024 ("Q4 Fiscal 2024" or "Fiscal 2024"). All f

Organigram Holdings Inc. (NASDAQ:OGI) (TSX:OGI), the parent company of Organigram Inc. (together, the "Company" or "Organigram"), a leading licensed producer of cannabis, announced today it will report earnings results for its fourth quarter and fiscal 2024 ended September 30, 2024, on Wednesday, December 18, 2024, prior to market open. The Company will host a conference call to discuss its results with details as follows: Date: Wednesday, December 18, 2024 Time: 8:00 am Eastern Time To register for the conference call, please use this link: https://registrations.events/direct/Q4I96766465 To ensure you are connected for the full call, we suggest registering a day in advance or at mi

Net revenue of $41.1 million increased 25% over the prior year period Adjusted EBITDA1 of $3.5 million versus $(2.9) million over the prior year period Established European foothold with a strategic investment in Sanity Group, a leading German cannabis company Completed landmark clinical study on FAST™ nanoemulsion technology showing faster onset, improved bioavailability of ingestible products Pro-forma cash position of $173 million2 Organigram Holdings Inc. (NASDAQ:OGI) (TSX:OGI), (the "Company" or "Organigram"), a leading licensed producer of cannabis, announced its results for the third quarter ended June 30, 2024 ("Q3 Fiscal 2024"). THIRD QUARTER HIGHLIGHTS Third q

Organigram Holdings Inc. (NASDAQ:OGI) (TSX:OGI), the parent company of Organigram Inc. (together, the "Company" or "Organigram"), a leading licensed producer of cannabis, announced today it will report earnings results for its third quarter fiscal 2024 ended June 30, 2024, on Tuesday, August 13, 2024, prior to market open. The Company will host a conference call to discuss its results with details as follows: Date: Tuesday, August 13, 2024 Time: 8:00 am Eastern Time To register for the conference call, please use this link: https://registrations.events/direct/Q4I9676663358 To ensure you are connected for the full call, we suggest registering a day in advance or at minimum 10 minutes

21% growth in recreational net revenue year-over-year First Jupiter private placement tranche closed adding $41.5 million of cash bringing Organigram's closing cash balance at quarter-end to $83.6 million Subsequent to quarter end, closed $28.8 million oversubscribed marketed offering, which when combined with the remaining two anticipated Jupiter tranches will increase cash position by additional $110 million Company's recent investment in Steady State LLC (d/b/a Open Book Extracts) ("OBX") adds to growing U.S. portfolio, which includes Phylos Bioscience Inc. ("Phylos") Organigram's U.S.-based strategic investments may benefit from expected change in rescheduling of cannabis b

Organigram Holdings Inc. (NASDAQ:OGI) (TSX:OGI), the parent company of Organigram Inc. (together, the "Company" or "Organigram"), a leading licensed producer of cannabis, announced today it will report earnings results for its second quarter fiscal 2024 ended March 31, 2024, on Tuesday, May 14, 2024, prior to market open. The Company will host a conference call to discuss its results with details as follows: Date: Tuesday, May 14, 2024 Time: 8:00 am Eastern Time To register for the conference call, please use this link: https://registrations.events/direct/Q4I9676693302 To ensure you are connected for the full call, we suggest registering a day in advance or at minimum 10 minutes bef

Achieved positive cash flow from operations, solidified #2 market position in Canada among licensed producers, significantly improved margins sequentially quarter-over-quarter, and closed first $41.5 million tranche of previously announced $124.6 million investment from BAT HIGHLIGHTS $124.6 million strategic investment from BAT announced in November 2023 approved by shareholders, with first of three tranches now funded at $3.22 per share for proceeds of $41.5 million Achieved positive Adjusted EBITDA1 and positive cash flow from operations of $7.7 million Improved sequential quarter-over-quarter adjusted gross margin2 from 17% in Q4 Fiscal 2023 (references to "Fiscal 2023" are t

Organigram Holdings Inc. (NASDAQ:OGI) (TSX:OGI), the parent company of Organigram Inc. (together, the "Company" or "Organigram"), a leading licensed producer of cannabis, announced today it will report earnings results for its first quarter fiscal 2024 ended December 31, 2023, on Tuesday, February 13, 2024, prior to market open. The Company will host a conference call to discuss its results with details as follows: Date: Tuesday, February 13, 2024 Time: 8:00 am Eastern Time To register for the conference call, please use this link: https://registrations.events/direct/Q4I967666846597333509997000 To ensure you are connected for the full call, we suggest registering a day in advance or

Domestic share growth in several key categories continues to be driven by innovation excellence and industry-leading R&D. Organigram continues to take a leadership position in industry fighting THC mislabelling (inflation). Company fortifying itself with recently announced BAT-Jupiter $124.6 million private placement transaction strengthening balance sheet and setting the stage for long-term growth outside of Canada. FISCAL 2023 HIGHLIGHTS At year-end, achieved the #2 position among Canadian licensed producers driven by success of growing pre-roll business2 Held the #1 position in the milled flower, gummies, and hash categories2 Held the #3 market position in Ontario, #3

Organigram Holdings Inc. (NASDAQ:OGI) (TSX:OGI), the parent company of Organigram Inc. (together, the "Company" or "Organigram"), a leading licensed producer of cannabis, announced today it will report earnings results for its fourth quarter and fiscal 2023 ended September 30, 2023, on Tuesday, December 19, 2023, before market open. The Company will host a conference call to discuss its results with details as follows: Date: Tuesday, December 19, 2023 Time: 8:00 am Eastern Time To register for the conference call, please use this link: https://conferencingportals.com/event/XWQpOvKk To ensure you are connected for the full call, we suggest registering a day in advance or at minimum 1

Year-to-date Canadian recreational business grew 10% versus prior year driven by continued focus on consumer-centric products and brands Strategic investments in Phylos and Greentank strengthen Organigram's position as an industry leader in cannabis innovation, solidifying long-term competitive advantage HIGHLIGHTS Recreational net revenue was $92.5 million for the nine months ended May 31, 2023, an increase of $8.0 million over the same prior-year period Increased sequential net revenue from Canadian recreational business by 7% vs. Q2 driven by continued success in hash and rebound in flower Organigram regained the #3 position in May and held it through June with 6.7% nation

Organigram Holdings Inc. (NASDAQ:OGI) (TSX:OGI), the parent company of Organigram Inc. (together, the "Company" or "Organigram"), a leading licensed producer of cannabis, announced today it will report earnings results for its third quarter fiscal 2023 ended May 31, 2023, on Thursday, July 13, 2023, after market close. The Company will host a conference call to discuss its results with details as follows: Date: Friday, July 14, 2023 Time: 8:00 am Eastern Time To register for the conference call, please use this link: https://conferencingportals.com/event/RUyBPhzX To ensure you are connected for the full call, we suggest registering a day in advance or at minimum 10 minutes before

Continues trend of improving Adjusted Gross Margin and fifth consecutive quarter of positive Adjusted EBITDA FINANCIAL HIGHLIGHTS Net revenue of $39.5 million, up 24% from $31.8 million in the same prior-year period. Adjusted Gross Margin1 of $13.4 million or 34%, compared to $8.3 million or 26% in the same prior year period, reflecting improvements from increased efficiencies, higher sales volume and increased international sales. Adjusted EBITDA1 of $5.6 million, the fifth consecutive quarter of positive Adjusted EBITDA, compared to Adjusted EBITDA of $1.6 million in the same prior year period. SALES AND OPERATIONAL HIGHLIGHTS In Q2 Fiscal 2023, maintained #3 position amo

Organigram Holdings Inc. (NASDAQ:OGI) (TSX:OGI), the parent company of Organigram Inc. (together, the "Company" or "Organigram"), a leading licensed producer of cannabis, announced today it will report earnings results for its second quarter fiscal 2023 ended February 28, 2023, on Tuesday, April 11, 2023, after market close. The Company will host a conference call to discuss its results with details as follows: Date: Wednesday, April 12, 2023 Time: 8:00 am Eastern Time To register for the conference call, please use this link: https://conferencingportals.com/event/RUyBPhzX To ensure you are connected for the full call, we suggest registering a day in advance or at minimum 10 minutes

Achieves record Adjusted Gross Margin and fourth consecutive quarter of positive Adjusted EBITDA FINANCIAL HIGHLIGHTS Net revenue of $43.3 million, up 43% from $30.4 million in the same prior-year period. Adjusted EBITDA1 of $5.6 million, the fourth consecutive quarter of positive Adjusted EBITDA, compared to negative Adjusted EBITDA of $1.9 million in the same prior year period. Adjusted Gross Margin1 of $12.8 million or 30%, compared to $5.5 million or 18% in the same prior year period, reflecting improvements from increased efficiencies and higher sales volume. SALES AND OPERATIONAL HIGHLIGHTS In Q1 Fiscal 2023, maintained #3 position among Canadian licensed producers2. Orga

Organigram Holdings Inc. (NASDAQ:OGI) (TSX:OGI), the parent company of Organigram Inc. (together, the "Company" or "Organigram"), a leading licensed producer of cannabis, announced today it will report earnings results for its first quarter fiscal 2023 ended November 30, 2022, on Thursday, January 12, 2023, before market open. The Company will host a conference call to discuss its results with details as follows: Date: Thursday, January 12, 2023 Time: 8:00 am Eastern Time To register for the conference call, please use this link: https://conferencingportals.com/event/RUyBPhzX To ensure you are connected for the full call, we suggest registering a day in advance or at minimum 10 minutes

Continues trend of record quarterly net revenue and positive Adjusted EBITDA while growing share of adult recreational market Q4 FISCAL 2022 FINANCIAL HIGHLIGHTS Continued record growth in net revenue, reaching $45.5 million, the highest in the history of the Company, up 83% from $24.9 million in the same prior-year period and 19% from $38.1 million in Q3 Fiscal 2022. Adjusted EBITDA1 of $3.2 million, the third consecutive quarter of positive Adjusted EBITDA, compared to negative Adjusted EBITDA of $4.8 million in the same prior year period. Adjusted Gross Margin1 of $10.4 million or 23%, compared to $3.0 million or 12% in the same prior year period, reflecting improvements from incr

Organigram Holdings Inc. (NASDAQ:OGI) (TSX:OGI), the parent company of Organigram Inc. (together, the "Company" or "Organigram"), a leading licensed producer of cannabis, announced today it will report earnings results for its annual and fourth quarter fiscal 2022 ended August 31, 2022 on Monday, November 28, 2022, after market close. The Company will host a conference call to discuss its results with details as follows: Date: Tuesday November 29, 2022 Time: 8:00 am Eastern Time To register for the conference call, please use this link: https://conferencingportals.com/event/RUyBPhzX To ensure you are connected for the full call, we suggest registering a day in advance or at minimum 10 m

Achieves fourth consecutive quarter of record net revenue and continues growth as a leading Canadian LP in recreational adult use market share HIGHLIGHTS Achieved gross revenue of $55.2 million, up 90% from the same prior-year period and 26% higher than Q2 Fiscal 2022 Continued record growth in net revenue, reaching $38.1 million, the highest in the history of the Company, up 88% from $20.3 million in the same prior-year period and 20% from $31.8 million in Q2 Fiscal 2022 In Q3 Fiscal 2022, achieved #3 position among Canadian licensed producers with 7.8% market share. In June 2022 the Company had 8.5% share of recreational adult use market 1 Continues to hold #1 position in dri

Organigram Holdings Inc. (NASDAQ:OGI) (TSX:OGI), the parent company of Organigram Inc. (together, the "Company" or "Organigram"), a leading licensed producer of cannabis, announced today it will report earnings results for its third quarter 2022 ended May 31, 2022 on Thursday, July 14, 2022 before market open. The Company will host a conference call to discuss its results with details as follows: Date: July 14, 2022 Time: 8:00 am Eastern Time To register for the conference call, please use this link: https://conferencingportals.com/event/RUyBPhzX To ensure you are connected for the full call, we suggest registering a day in advance or at minimum 10 minutes before the start of the call.

Achieves positive Adjusted EBITDA two quarters earlier than expected driven by record high net revenue for the Company of $31.8 million and a top 3 national market share position among Canadian LPs. HIGHLIGHTS Achieved gross revenue of $43.9 million, up 128% from the same prior-year period and consistent with Q1 Fiscal 2022, despite the impact of seasonality Continued record growth in net revenue, reaching $31.8 million, the highest in the history of the Company, up 117% from $14.6 million in the same prior-year period and 5% from $30.4 million in Q1 Fiscal 2022 Achieved positive Adjusted EBITDA of $1.6 million, two quarters ahead of the Company's initial estimate Reached 8.2% m

Organigram Holdings Inc. (NASDAQ:OGI) (TSX:OGI), the parent company of Organigram Inc. (together, the "Company" or "Organigram"), a leading licensed producer of cannabis, announced today it will report earnings results for its second quarter 2022 ended February 28, 2022 on Tuesday, April 12, 2022 before market open. The Company will host a conference call to discuss its results with details as follows: Date: April 12, 2022 Time: 8:00 am Eastern Time To register for the conference call, please use this link: https://conferencingportals.com/event/RUyBPhzX To ensure you are connected for the full call, we suggest registering a day in advance or at minimum 10 minutes before the start of the

$30.4 million net revenue represents a record for the Company as it solidifies #4 market share position nationally among Canadian LPs HIGHLIGHTS 23% growth in gross revenue to $44.3 million from Q4 Fiscal 2021 and 75% from the same prior-year period Achieved highest quarterly net revenue in the history of the Company at 22% growth to $30.4 million, from $24.9 million in Q4 Fiscal 2021 and 57% growth from $19.3 million in Q1 2021 Maintained market share position as #4 Canadian LP with 7.5% market share, up from 4.4% share in Q1 Fiscal 20211 SHRED popularity continues with Tropic Thunder and Funk Master achieving #1 and #2 positions respectively in November as the best-selling flower

Organigram Holdings Inc. (NASDAQ:OGI) (TSX:OGI), the parent company of Organigram Inc. (together, the "Company" or "Organigram"), a leading licensed producer of cannabis, announced today it will report earnings results for its first quarter fiscal 2022 ended November 30, 2021 on Tuesday, January 11, 2022 before market open. The Company will host a conference call to discuss its results with details as follows: Date: January 11, 2022 Time: 8:00 am Eastern Time To register for the conference call, please use this link: http://www.directeventreg.com/registration/event/7385048 To ensure you are connected for the full call, we suggest registering a day in advance or at minimum 10 minutes bef

Continued growth in net revenue and increased market share Achieved a 7% share of market in the recreational cannabis market in Q4, up from 5.4% in Q3 2021, positioning Organigram as the #4 licensed producer and the momentum continues with a 7.9% share of market as of October.1 24% growth in gross revenue to $36.2 million in Q4 2021 from Q3 2021 and 43% from the same prior-year period 22% growth in net revenue to $24.9 million in Q4 2021 from Q3 2021 and 22% from the same prior-year period 36% growth in recreational net revenue to $22.9 million in Q4 2021 from Q3 2021 and 52% from the same prior-year period Launched 16 new stock-keeping units (SKUs) in the recreational channel S

Organigram Holdings Inc. (NASDAQ:OGI) (TSX:OGI), the parent company of Organigram Inc. (together, the "Company" or "Organigram"), a leading licensed producer of cannabis, announced today it will report earnings results for its fourth quarter and full year fiscal 2021 ended August 31, 2021 on Tuesday, November 23, 2021 before market open. The Company will host a conference call to discuss its results with details as follows: Date: November 23, 2021 Time: 8:00 am Eastern Time To register for the conference call, please use this link: http://www.directeventreg.com/registration/event/4654838 To ensure you are connected for the full call, we suggest registering a day in advance or at minimum